- Joined
- 30 June 2008
- Posts
- 15,357
- Reactions
- 7,232
Some members might be aware of the unravelling of the multi-billion dollar Valeant Pharmaceutical Co. Essentially it looks like re -run of Enron and when one reads what has gone down so far it seems highly unlikely to have a happier ending.
This is a company that was valued $90billion earlier this year. Wonder what the impact will be on the markets as it plays out.
Interestingly enough one of the first people to call it out as dodgy was John Hempton from Bronte Capital. He has a long history of identifying companies that have doubtful legitimacy, outlining the case and then shorting the hell out of them.
http://brontecapital.blogspot.com.au/
This is a company that was valued $90billion earlier this year. Wonder what the impact will be on the markets as it plays out.
Interestingly enough one of the first people to call it out as dodgy was John Hempton from Bronte Capital. He has a long history of identifying companies that have doubtful legitimacy, outlining the case and then shorting the hell out of them.
http://brontecapital.blogspot.com.au/
http://www.canberratimes.com.au/bus...n-moment-for-the-markets-20151023-gkgnxs.htmlIs this an Enron moment for the markets?
Date
October 24, 2015
HAS THE ENRON MOMENT ARRIVED IN THE US?
In June last year the founder of the Sydney-based Bronte Capital hedge fund, John Hempton, began blogging about a Wall Street superstar, Valeant Pharmaceuticals.
Valeant's shares had risen from around $US7 to $US129 in just over half a decade on the back of dozens of acquisitions by the time Hempton disclosed that he was shorting the stock, and explained why.
They continued rising and hit $US262.52 in August, valuing Valeant at just under $90 billion. Since then, they have more than halved to $US110, and in the past week – after the publication of reports alleging that Valeant has been pumping up its revenue – they have plunged 37 per cent, slashing Valeant's market value by more than $US20 billion.
The first thing Hempton did last year was point out that Valeant was reporting sensational growth in earnings that were adjusted for what it classed as non-recurring takeover costs, but reporting losses using America's default GAAP (Generally Accepted Accounting Principles) accounting template.
Debt was more than 15 times Valeant's GAAP cash flow, he said, adding that on that measure, Valeant was a goner.